Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Verrill

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Cancer|June 2, 2005
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II studyD Serin, M Verrill, A Jones, et al.
British Journal of Cancer|August 22, 2013
Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumoursV R Bulusu, J Fullarton, M Leahy, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBCK Malinovszky, S Johnston, P Barrett-Lee, et al.
British Journal of Cancer|February 3, 2005
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancerA Urruticoechea, C D Archer, L A Assersohn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
NPJ Breast Cancer|February 13, 2026
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumourS Blacker, K Horgan, D A Cromwell, et al.
NMR in Biomedicine|December 22, 1998
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatmentM O Leach, M Verrill, J Glaholm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2005
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)S Chua, I E Smith, R P A'Hern, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Cancer|June 2, 2005
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II studyD Serin, M Verrill, A Jones, et al.
British Journal of Cancer|August 22, 2013
Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumoursV R Bulusu, J Fullarton, M Leahy, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBCK Malinovszky, S Johnston, P Barrett-Lee, et al.
British Journal of Cancer|February 3, 2005
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancerA Urruticoechea, C D Archer, L A Assersohn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
NPJ Breast Cancer|February 13, 2026
Evaluation of methods to classify ipsilateral breast tumour recurrences as local recurrence or new primary tumourS Blacker, K Horgan, D A Cromwell, et al.
NMR in Biomedicine|December 22, 1998
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatmentM O Leach, M Verrill, J Glaholm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2005
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)S Chua, I E Smith, R P A'Hern, et al.
Pageof 2